Bone marrow-derived mesenchymal stem cell transplantation attenuates overexpression of inflammatory mediators in rat brain after cardiopulmonary resuscitation

Q, Lin; Tang, Xiahong; Lin, Shirong; Chen, Ben-Dun; Chen, Feng

doi:10.4103/1673-5374.265563

Cited by 16 publications

(14 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 BM-MSC administration protected the brain against ischemic injury after cardiac arrest and stroke by reducing inflammation, inhibiting the C-Jun N-terminal kinase pathway, and releasing exosomes containing miR-138-5p. 22,[58][59][60] A translational phase I study of chronic stroke patients demonstrated the safety of intravenously transfused allogeneic, ischemia-tolerant BM-MSCs, as well as behavioral gains 1 year after treatment. This early study raised exciting potential for the application of this therapy in stroke.…”

Section: Bone Marrow-derived Mscsmentioning

confidence: 99%

“…IV injection of BM-MSCs, but not AD-MSCs, improved survival rates, anti-inflammatory cytokine levels, and growth factors in a neonatal hypoxic-ischemic brain injury rat model [ 52 ]. BM-MSC administration protected the brain against ischemic injury after cardiac arrest and stroke by reducing inflammation, inhibiting the C-Jun N-terminal kinase pathway, and releasing exosomes containing miR-138-5p [ 22 , 58 - 60 ]. A translational phase I study of chronic stroke patients demonstrated the safety of intravenously transfused allogeneic, ischemia-tolerant BM-MSCs, as well as behavioral gains 1 year after treatment.…”

Section: Stem Cell Sourcesmentioning

confidence: 99%

See 1 more Smart Citation

Optimizing Stem Cell Therapy after Ischemic Brain Injury

et al. 2020

View full text Add to dashboard Cite

Stem cells have been used for regenerative and therapeutic purposes in a variety of diseases. In ischemic brain injury, preclinical studies have been promising, but have failed to translate results to clinical trials. We aimed to explore the application of stem cells after ischemic brain injury by focusing on topics such as delivery routes, regeneration efficacy, adverse effects, and <i>in vivo</i> potential optimization. PUBMED and Web of Science were searched for the latest studies examining stem cell therapy applications in ischemic brain injury, particularly after stroke or cardiac arrest, with a focus on studies addressing delivery optimization, stem cell type comparison, or translational aspects. Other studies providing further understanding or potential contributions to ischemic brain injury treatment were also included. Multiple stem cell types have been investigated in ischemic brain injury treatment, with a strong literature base in the treatment of stroke. Studies have suggested that stem cell administration after ischemic brain injury exerts paracrine effects via growth factor release, blood-brain barrier integrity protection, and allows for exosome release for ischemic injury mitigation. To date, limited studies have investigated these therapeutic mechanisms in the setting of cardiac arrest or therapeutic hypothermia. Several delivery modalities are available, each with limitations regarding invasiveness and safety outcomes. Intranasal delivery presents a potentially improved mechanism, and hypoxic conditioning offers a potential stem cell therapy optimization strategy for ischemic brain injury. The use of stem cells to treat ischemic brain injury in clinical trials is in its early phase; however, increasing preclinical evidence suggests that stem cells can contribute to the down-regulation of inflammatory phenotypes and regeneration following injury. The safety and the tolerability profile of stem cells have been confirmed, and their potent therapeutic effects make them powerful therapeutic agents for ischemic brain injury patients.

show abstract

Section: Bone Marrow-derived Mscsmentioning

confidence: 99%

Section: Stem Cell Sourcesmentioning

confidence: 99%

Optimizing Stem Cell Therapy after Ischemic Brain Injury

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previous studies have found that transplantation with BMSCs relieves brain pathology and neurofunctional disturbance in CA/CPR rat model 32,33 . Our recent study demonstrated that transplantation with BMSCs attenuates brain damage in a rat CA model by decreasing levels of inflammatory factors and increasing levels of anti‐inflammatory cytokines 34 . Although few studies have examined the effect of BMSC‐based therapies on reducing neural pyroptosis, there is evidence that BMSCs transplantation can improve neurological function 35–37 …”

Section: Introductionmentioning

confidence: 95%

“…32,33 Our recent study demonstrated that transplantation with BMSCs attenuates brain damage in a rat CA model by decreasing levels of inflammatory factors and increasing levels of anti-inflammatory cytokines. 34 Although few studies have examined the effect of BMSCbased therapies on reducing neural pyroptosis, there is evidence that BMSCs transplantation can improve neurological function. [35][36][37] However, recent studies have shown that transplanted cells can be limited by the global and regional tissue microenvironment, decreasing the efficacy of BMSCs.…”

Section: Introductionmentioning

confidence: 99%

Hypoxic preconditioned mesenchymal stem cells ameliorate rat brain injury after cardiopulmonary resuscitation by suppressing neuronal pyroptosis

Tang

Chen

et al. 2023

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

show abstract

“…We selected five of the most commonly used carrier solutions in MSCs transplantation for clinical and experimental purposes, namely 0.9% saline (saline) [17], phosphate-buffered solution (PBS) [18], 5% dextrose solution (5% DS) [19], heparin in saline (Hepa-Sal) (1 IU/mL) [20], and Hartmann's solution (HS) [21].…”

Section: Introductionmentioning

confidence: 99%

Effects of carrier solutions on the viability and efficacy of canine adipose-derived mesenchymal stem cells

et al. 2022

View full text Add to dashboard Cite

Background Mesenchymal stem cells (MSCs) have favorable characteristics that render them a potent therapeutic tool. We tested the characteristics of MSCs after temporal storage in various carrier solutions, such as 0.9% saline (saline), 5% dextrose solution (DS), heparin in saline, and Hartmann’s solution, all of which are approved by the U.S. Food and Drug Administration (FDA). Phosphate-buffered saline, which does not have FDA approval, was also used as a carrier solution. We aimed to examine the effects of these solutions on the viability and characteristics of MSCs to evaluate their suitability and efficacy for the storage of canine adipose-derived MSCs (cADMSCs). Results We stored the cADMSCs in the test carrier solutions in a time-dependent manner (1, 6, and 12 h) at 4 °C, and analyzed cell confluency, viability, proliferation, self-renewability, and chondrogenic differentiation. Cell confluency was significantly higher in 5% DS and lower in phosphate-buffered saline at 12 h compared to other solutions. cADMSCs stored in saline for 12 h showed the highest viability rate. However, at 12 h, the proliferation rate of cADMSCs was significantly higher after storage in 5% DS and significantly lower after storage in saline, compared to the other solutions. cADMSCs stored in heparin in saline showed superior chondrogenic capacities at 12 h compared to other carrier solutions. The expression levels of the stemness markers, Nanog and Sox2, as well as those of the MSC surface markers, CD90 and CD105, were also affected over time. Conclusion Our results suggest that MSCs should be stored in saline, 5% DS, heparin in saline, or Hartmann’s solution at 4 °C, all of which have FDA approval (preferable storage conditions: less than 6 h and no longer than 12 h), rather than storing them in phosphate-buffered saline to ensure high viability and efficacy.

show abstract

Bone marrow-derived mesenchymal stem cell transplantation attenuates overexpression of inflammatory mediators in rat brain after cardiopulmonary resuscitation

Cited by 16 publications

References 48 publications

Optimizing Stem Cell Therapy after Ischemic Brain Injury

Optimizing Stem Cell Therapy after Ischemic Brain Injury

Hypoxic preconditioned mesenchymal stem cells ameliorate rat brain injury after cardiopulmonary resuscitation by suppressing neuronal pyroptosis

Effects of carrier solutions on the viability and efficacy of canine adipose-derived mesenchymal stem cells

Contact Info

Product

Resources

About